Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BRENTUXIMAB

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Almost all HL and some NHL express the CD30 antigen, and monoclonal antibodies (mAb) targeting CD30 (e.g. brentuximab) produce… Expand
Is this relevant?
Highly Cited
2017
Highly Cited
2017
BACKGROUND Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
  • Cristina Scavone, Liberata Sportiello, +10 authors G. M. A. F. R. R. M. L. E. A. G. V. V. M. G. M. Valentini Romano Lo Schiavo Morgillo Nuzzetti D'An
  • Front. Pharmacol.
  • 2017
  • Corpus ID: 23665856
Objectives: To investigate the occurrence of adverse events (AEs) in naïve patients receiving biotech drugs. Design: A… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
2017
2017
Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic… Expand
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Monoclonal antibody therapy is a new innovation in cancer therapy. Binding of monoclonal antibodies to tumor cells facilitates… Expand
Is this relevant?
2016
2016
Acute pulmonary toxicity associated with brentuximab appears to be a rare but serious adverse effect that can be potentially… Expand
  • figure 1
Is this relevant?
2016
2016
Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with… Expand
  • figure 1
Is this relevant?
2015
2015
Among haematological malignancies, Hodgkin’s lymphoma (HL) remains a disease with a high cure rate and overall survival rate of… Expand
  • table 1
  • table 2
Is this relevant?
2013
2013
![Graphic][1] In hematological disorders ALK expression is present in >50% of Anaplastic Large Cell Lymphomas (ALCL) as a… Expand
Is this relevant?
Review
2013
Review
2013
With the recent approvals of brentuximab for the treatment of refractory Hodgkin lymphoma and ado-trastuzumab emtansine for… Expand
  • table 1
Is this relevant?